Physician profile
Anna Handy
NPI 1154951333
$1,215.47
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $194.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $222.70 | 2021-2022 | |
| Lilly USA, LLC | $213.80 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $176.35 | 2021-2022 | |
| Ucb, INC. | $163.92 | 2021 | |
| Journey Medical Corporation | $97.61 | 2021-2022 | |
| Leo Pharma INC. | $95.49 | 2021-2022 | |
| Galderma Laboratories, L.P. | $44.35 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.16 | 2021 | |
| Mayne Pharma Commercial LLC | $30.43 | 2021 | |
| Vyne Pharmaceuticals INC. | $29.28 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $26.75 | 2022 | |
| Incyte Corporation | $24.21 | 2021 | |
| Dermira, INC. | $18.33 | 2021 | |
| Genzyme Corporation | $17.77 | 2021 | |
| Amgen INC. | $13.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Handy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.